AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03765060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monomax® 2/0 HR26
Description: It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 2/0 with HR 26 needle.~In the technique should be given at least 2 points for each wound cm, with a distance to the alba line of 0'5cm and 0'5 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1.
Study NCT03765060 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monomax® 1 HR48
Description: It will be use a very long-term monofilament absorbable synthetic suture of Poly-4-hydroxybutyrate (Monomax) 1 with HR 48 needle.~In the technique should be given 1 point for each wound cm, with a distance to the alba line of 1 cm and 1 cm of separation between stitches. The closure starts from both ends, ending in the middle of the laparotomy with an overlap of at least 2 cm. The ratio between the length of the suture and the length of the wound should be at least 4:1.
Study NCT03478371 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tampon D
Description: regular absorbency tampon
Study NCT03478371 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tampon M
Description: regular absorbency tampon
Study NCT03478371 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tampon T
Description: regular absorbency tampon
Study NCT03478371 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tampon V
Description: regular absorbency tampon
Study NCT02935569 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression HeadBand
Description: * commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion~* Plastics disks, hollow (3.5 cm diameter, by 1 cm height)~Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery.
Study NCT05673356 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB)
Description: Arthroscopic anterior cruciate ligament reconstruction with quadriceps tendon bone autograft (QTB) will be performed in these patients. QTB autografts will be harvested as described in the published technique: K. Malinowski, J. Paszkowski, M. Mostowy, A. Góralczyk, R.F. LaPrade, K. Hermanowicz, Quadriceps Tendon-Bone Full-Thickness Autograft: Reproducible and Easy Harvesting Technique Using Simple Surgical Tools, Arthrosc. Tech. 10 (2021) e1165-e1172. https://doi.org/10.1016/j.eats.2021.01.003. ACLR will be performed utilizing anteromedial technique with management of any accompanying intraarticular lesions.
Study NCT00564941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: deferasirox
Study NCT03308240 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magic Therapy
Description: As described in the arm description
Study NCT02667925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin with nanocis
Description: Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
Study NCT04633746 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: measuring plasma Endostatin level
Description: measuring plasma Endostatin level at the time of admission then after 48hrs and 96 hours
Study NCT03573037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral anticoagulant
Description: 1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
Study NCT03573037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral anticoagulant
Description: 1:1 randomization to 1-month anticoagulation or 2-month anticoagulation after radiofrequency catheter ablation of paroxismal atrial fibrillation
Study NCT03954093 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
Study NCT03954093 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
Study NCT03954093 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS produces hyper/hypopolarizing potentials in the cortex underlying the scalp electrodes and can increase/decrease the excitability of targeted brain regions.
Study NCT03303495 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
Study NCT03303495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: 180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
Study NCT03303495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU Bolus
Description: 400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
Study NCT03303495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU Infusion
Description: 2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
Study NCT03303495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: l-LV (dl-LV)
Description: 200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
Study NCT01776970 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis Sativa extract Oromucosal spray
Description: Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
Study NCT01776970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Sativa extract Oromucosal spray
Description: Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
Study NCT01558219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabacitaxel
Description: Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
Study NCT01656395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1029
Description: MK-1029 10 mg, 30 mg or 150 mg oral tablets taken QD at bedtime, based on randomization.
Study NCT01468181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfonylureas (SU)
Description: SU is a pre-study prescribed dose and is not being provided as part of the trial.
Study NCT01468181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biguanides (BG)
Description: Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
Study NCT01468181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpha-glucosidase inhibitor (a-GI)
Description: a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
Study NCT01468181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione (TZD)
Description: TZD is a pre-study prescribed dose and is not being provided as part of the trial.
Study NCT01468181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glinides
Description: Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
Study NCT03591653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15028
Description: The investigational products are administrated orally, once in the morning every day, and each dose includes one tablet of investigational products (LXI-15028 50mg active agent or placebo). If the investigational product is not taken in the morning, subjects can take it before 6:00 p.m. on the same day. The duration of treatment is 4 weeks.
Study NCT03591653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01940133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PQR309
Description: Dosing will be orally, once a day for the duration of the trial.
Study NCT03529682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 10 minutes warm-up exercises and stretching exercises, 40 mınutes consecutive exercises (strengthening exercises for trunk and lower extremities) and 10 mınutes cooling down exercises and stretching exercises will be applied.
Study NCT03529682 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: 60 mınutes in a day and 3 times in a week traditional physiotherapy program will be applied
Study NCT01656395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast 10 mg
Description: Parts I-II: Participants will receive Montelukast 10 mg tablets QD
Study NCT01656395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Description: Parts I-II: Participants will receive Montelukast 10 mg tablets QD
Study NCT01656395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Parts I-II: Participants will receive Placebo tablets QD
Study NCT03871153 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Durvalumab
Description: Neoadjuvant Durvalumab 750 mg IV on Days 1, 15 and 29~Adjuvant Durvalumab 12 weeks after undergoing surgical resection 1,500 mg IV on Day 1
Study NCT03871153 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: Paclitaxel 45 mg/m2 IV Days 1, 8, 15, 22, 29 and +/- 36
Study NCT03871153 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: Carboplatin AUC of 2 IV Days 1, 8, 15, 22, 29 +/- 36
Study NCT03871153 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Description: 1.8-2.0 Gy per day (5 days/week) for a total of 45-61.2 Gy over 5-6 weeks. Treatment will be delivered using IMRT or 3DCRT using typically 6-10MV photons. Proton therapy is also allowed. 4D simulation and appropriate IGRT are encouraged. Radiation therapy must begin within one week of the first day of chemotherapy (or vice versa).
Study NCT04293458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EsoGuard
Description: EsoGuard assay (LDT) will be used on cells collected using EsoCheck (510K cleared esophageal cell collection device) and compared to results of EGD plus biopsies (when taken)
Study NCT01827644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib GC - Fasted State
Description: White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state
Study NCT01827644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib HPMC capsule - Fasted State
Description: White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
Study NCT03871153 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical Resection
Description: Patients will undergo repeat imaging between 4 and 12 weeks after completing neoadjuvant therapy. Those without evidence of progressive disease and found to be a surgical candidate by a thoracic surgeon will undergo surgical resection between 4 and 12 weeks after neoadjuvant therapy.
Study NCT04503967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride With Nivolumab
Description: Anlotinib Hydrochloride Combined With Nivolumab in the second line Treatment of Gastric and Esophageal Cancer patients
Study NCT03669549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevanimibe hydrochloride
Description: During the 16-week treatment period, all subjects will begin dosing with nevanimibe HCl 500 mg BID and be dose titrated to 1000 mg BID, 1500 mg BID, and 2000 mg BID as needed based on serum 17-OHP assessments every 4 weeks.
Study NCT02168491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide
Description: Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
Study NCT01827644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib ECT - Fasted State
Description: White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state
Study NCT01827644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib GC - Fed State
Description: White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state
Study NCT01827644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib HPMC capsule - Fed State
Description: White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
Study NCT01827644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib ECT - Fed State
Description: White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state
Study NCT01810458 — intervention group
Intervention type: DEVICE
Intervention: Abdominal ultrasound
Description: Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
Study NCT01810458 — intervention group
Intervention type: PROCEDURE
Intervention: History and physical
Description: Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
Study NCT01810458 — intervention group
Intervention type: PROCEDURE
Intervention: Intravenous catheter
Description: Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
Study NCT01810458 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw
Description: At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
Study NCT01810458 — intervention group
Intervention type: OTHER
Intervention: Liver questionnaire
Description: At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
Study NCT01810458 — intervention group
Intervention type: PROCEDURE
Intervention: Liver Biopsy
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
Study NCT01810458 — intervention group
Intervention type: DRUG
Intervention: Midazolam
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Study NCT01810458 — intervention group
Intervention type: DRUG
Intervention: Fentanyl
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Study NCT01810458 — intervention group
Intervention type: DRUG
Intervention: Lidocaine
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Study NCT01810458 — intervention group
Intervention type: DRUG
Intervention: Acetaminophen
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Study NCT01810458 — intervention group
Intervention type: DRUG
Intervention: Lorazepam
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Study NCT01810458 — intervention group
Intervention type: DRUG
Intervention: Oxycodone/Acetaminophen
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Study NCT01810458 — intervention group
Intervention type: DRUG
Intervention: Ondansetron
Description: Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
Study NCT01012297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT01012297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT01012297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given SC
Study NCT01012297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01012297 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Given SC
Study NCT01012297 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given IV
Study NCT02235311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
Study NCT02861235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary
Description: with gamma-camera and D.SPECT camera